Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of rapcabtagene autoleucel versus comparator in severe active GPA or MPA
MOH_2026-01-12_015597Phase 2Recruiting
- Sponsor
- Novartis
- Start
- Feb 2025
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Vaccines & Immunotherapeutics, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rapcabtagene autoleucel in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) (3 cohorts), sponsored by Novartis. Started Feb 2025; status: recruiting.
02
Drugs
rapcabtagene autoleucel
03
Conditions
granulomatosis with polyangiitis (GPA)microscopic polyangiitis (MPA)
Beyond the preview
Go deeper on MOH_2026-01-12_015597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-01-12_015597.